Phase 3 trial demonstrates clinically meaningful reduction in tic severity in Tourette syndrome without metabolic side effects, highlighting ecopipam as a safe therapeutic option.
The novel selective dopamine D1 receptor antagonist ecopipam resulted in clinically meaningful improvement in the severity of tics in patients with Tourette syndrome, a Phase 3 trial has found. Ecopipam resulted in no significant changes in metabolic measures and no reports of movement disorders, the investigators reported. Study results were published online May 26, 2026 in JAMA Neurology .
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: